ArticlePharmacoEconomics2024

Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.

Zakile A Mfumbilwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.